p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

May 31, 2012

Study Completion Date

December 31, 2012

Conditions
Esophageal Cancer
Interventions
DRUG

5-Fluoruracil, Cisplatinum

"5 FU 1000mg/m2; days 1-5; 3 cycles: q21~Cisplatin 80mg/m2; day 1; 3 cycles: q21"

DRUG

Docetaxel

Docetaxel 75mg/m2, day 1; 3 cycles; q21

Trial Locations (13)

1030

Rudolfstiftung, Vienna

1090

Medical University of Vienna, Vienna

1100

Kaiser Franz Josef Spital, Vienna

1140

Hanusch Krankenhaus, Vienna

2700

Landesklinikum Wiener Neustadt, Wiener Neustadt

3100

Landesklinikum St. Pölten, Sankt Pölten

4020

Krankenhaus der Elisabethinen, Linz

8790

Landeskrankenhaus Leoben, Leoben

9300

Krankenhaus der Barmherzigen Brüder, Stankt Veit

Unknown

Medical University Innsbruck, Innsbruck

SMZ OST, Vienna

Wilhelminenspital, Vienna

Landesklinikum Feldkirch, Feldkirch

All Listed Sponsors
collaborator

Medical University of Vienna

OTHER

collaborator

Austrian Society Of Surgical Oncology

OTHER

lead

Daniela Kandioler

OTHER

NCT00525200 - p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer | Biotech Hunter | Biotech Hunter